Following last year's test of FHIR Genomics, a diverse set of organizations will look to demonstrate that the standard can help them feed genomic data to EHRs.
By pulling in data from Higi health kiosks in retail pharmacies, Interpreta builds continuously updated care from genomics, clinical data, and patient lifestyles.
Genomic informatics startups Gene42 and SeqOne announced a technology partnership that seeks to improve the yield and speed of rare disease diagnosis.
Startup Optra Health has added Alexa and Cortana compatibility to its AI platform to help consumers understand Ancestry.com- and 23andMe-type genetic tests.
At the HL7 Genomics Conference, a FHIR Genomics developer unveiled the Consortium for Agile Genomics to promote implementation of the nascent standard.
The latest release of Sophia AI merges imaging analysis with genomic medicine in pursuit of better diagnosis and treatment.
Meditech, one of the oldest existing EHR companies, has staked out a role in supporting precision medicine with drug-gene interaction testing.
Irish rare disease research center FutureNeuro is partnering with software vendor Congenica to bring sequencing to the point of care for genetic epilepsies.
Sentieon will integrate its DNAseq and TNseq variant-calling technology into Qiagen's CLC Genomics Workbench and the Qiagen Clinical Insight platform.
Genome Canada and its partners recently funded two new initiatives with C$255 that will back precision medicine, genomics, and technology development.
Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.
The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.
Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.
In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.